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fasting conditions (B = −0.024 [−0.045, −0.002]) and 
2 h after glucose tolerance test (B = −0.099 [−0.158, 
−0.039]), but not with HbA1c (B = 0.000 [−0.014, 
0.013]), after adjustment for relevant factors. In prospec-
tive analyses (n = 257), serum LA was not associated with 
fasting (B = 0.003 [−0.019, 0.025]) or post-load glucose 
(B = −0.026 [−0.100, 0.049]). Furthermore, no significant 
associations were found between serum ALA and glucose 
metabolism in cross-sectional or prospective analyses.
Conclusions In this study, serum LA was inversely associ-
ated with fasting and post-load glucose in cross-sectional, 
but not in prospective analyses. Further studies are needed 
to elucidate the exact role of serum LA and ALA levels and 
dietary polyunsaturated fatty acids in glucose metabolism.
Keywords Serum fatty acids · Linoleic acid ·  
Alpha-linolenic acid · Type 2 diabetes · Glucose · 
Hemoglobin A1c
Abstract 
Purpose Data on the relation between linoleic acid (LA) 
and alpha-linolenic acid (ALA) and type 2 diabetes mel-
litus (T2DM) risk are scarce and inconsistent. The aim of 
this study was to investigate the association of serum LA 
and ALA with fasting and 2 h post-load plasma glucose and 
glycated hemoglobin (HbA1c).
Method This study included 667 participants from third 
examination (2000) of the population-based Hoorn study 
in which individuals with glucose intolerance were over-
represented. Fatty acid profiles in serum total lipids were 
measured at baseline, in 2000. Diabetes risk markers were 
measured at baseline and follow-up in 2008. Linear regres-
sion models were used in cross-sectional and prospective 
analyses.
Results In cross-sectional analyses (n = 667), serum LA 
was inversely associated with plasma glucose, both in 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00394-016-1261-6) contains supplementary 
material, which is available to authorized users.
 * Mieke Cabout 
 mieke.cabout@vu.nl
1 Department of Health Sciences and EMGO Institute 
for Health and Care Research, Vrije Universiteit Amsterdam, 
Amsterdam, The Netherlands
2 Unilever Research and Development, Vlaardingen, The 
Netherlands
3 Department of Epidemiology and Biostatistics and EMGO 
Institute for Health and Care Research, VU University 
Medical Center, Amsterdam, The Netherlands
4 Department of General Practice and EMGO Institute 
for Health and Care Research, VU University Medical 
Center, Amsterdam, The Netherlands
5 Department of Internal Medicine and Cardiovascular 
Research Institute Maastricht (CARIM), Maastricht 
University Medical Centre, Maastricht, The Netherlands
6 Institute of Basic Medical Sciences, Department of Nutrition, 
University of Oslo, Oslo, Norway
7 Department of Pharmacology, University of Oxford, Oxford, 
UK
 Eur J Nutr
1 3
Introduction
Dietary fatty acids affect blood lipid concentrations [1] and 
are related to the risk of developing coronary heart disease 
(CHD) [2]. Therefore, most nutrition recommendations 
advise to limit intakes of saturated fatty acids (SFA) and 
trans fats and replace these with unsaturated fatty acids, 
in particular polyunsaturated fatty acids (PUFA) for opti-
mal CHD risk reduction, which in the diet mainly occur 
as omega-6 linoleic acid (LA) and omega-3 alpha-linoleic 
acid (ALA) [3–5].
Type 2 diabetes mellitus (T2DM) is a rapidly grow-
ing chronic metabolic disease [6] that not only confers a 
high risk of complications, but also puts a heavy burden on 
patients’ quality of life and on healthcare resources. Data 
on the role of dietary fatty acid intake, in particular on the 
plant-based PUFA linoleic acid (LA) and alpha-linolenic 
acid (ALA), in the development of T2DM are limited. 
According to FAO/WHO guidelines, there is probable but 
inconclusive evidence that increasing LA lowers the risk of 
developing T2DM [7]. Some prospective cohorts reported 
that higher dietary LA intake is associated with lower 
T2DM risk [8–10], while others showed no significant 
associations [11–13] or even a positive association [14].
Dietary intake is often difficult to determine due to the 
limited accuracy of the measurement and the food com-
position tables, and the tendency to underestimate total 
energy intake including fat intake [15, 16]. The intake of 
the nonendogenously produced fatty acids LA and ALA 
can also be assessed more objectively via measurement of 
circulating fatty acids in serum, plasma or erythrocytes. 
These levels provide a relatively accurate reflection of the 
dietary fatty acid intake [17] over past several weeks or 
months [18]. The association of fatty acids in serum, but 
more often in plasma or erythrocytes, with T2DM has been 
investigated in a few prospective studies. Most research-
ers observed that higher proportions of LA were associ-
ated with a significantly lower T2DM risk [11, 13, 19–22], 
but others found no association [23]. A recent systematic 
review on the omega-3 fatty acids ALA, eicosapentaenoic 
acid (EPA), and docosahexaenoic acid (DHA), including 
six cohorts, concluded that higher circulating ALA and not 
EPA or DHA was associated with a nonsignificant trend 
toward lower risk of T2DM [24].
Researchers that studied both the fatty acid intake from 
diet and fatty acids in the circulation concluded that associ-
ations with diabetes risk were stronger with the use of cir-
culating LA and ALA blood levels than with dietary intakes 
assessed by food frequency questionnaire (FFQ) [11, 13, 
14]. Most earlier studies on these fatty acids and diabetes 
incidence relied on diagnosed, self-reported diabetes which 
is an underestimation of the total burden of diabetes. It is 
estimated that worldwide, half of the diabetes patients are 
undiagnosed [6]. In the present study, all current markers 
used to diagnose T2DM were measured [11]. In this data 
set, we investigated the cross-sectional and the prospective 
associations of serum LA or ALA with fasting plasma glu-




The Hoorn study is an observational cohort study on glu-
cose metabolism in the general Dutch Caucasian popula-
tion which included 2484 participants, aged 50–74 years at 
study initiation in 1989. The detailed research design and 
methods of this initial Hoorn Study are described elsewhere 
[25]. For the examination cycle in 2000–2001, an invitation 
was sent to all surviving patients with T2DM (n = 176) and 
random samples of individuals with impaired glucose tol-
erance (n = 193) and normal glucose tolerance (n = 705), 
based on their glucose tolerance status at the 1996–1998 
examination. Of all invited participants, 648 (60 %) partici-
pated in this study [26]. In addition, 195 (90 %) of the 217 
newly diagnosed patients with T2DM from Hoorn screen-
ing study (1998–2000) were included, as well as 60 diabe-
tes patients, newly diagnosed in general practice [27]. We 
excluded people taking oral glucose lowering medication 
(n = 48), patients with known diabetes at previous Hoorn 
study examinations (n = 19), people with missing informa-
tion on diabetes status (n = 15), and people with missing 
information on serum fatty acids (n = 154). In total, 667 
individuals were included in the current cross-sectional 
analyses. Of the n = 667 participants at baseline, n = 417 
participated in the follow-up examination performed in 
2008, where they underwent an interview to obtain gen-
eral and medical history-related information, a physical 
examination, and analysis of blood samples [28]. For the 
prospective analysis, we additionally excluded all baseline 
T2DM patients (n = 160) because treatment initiation may 
have impacted on the outcomes. The 257 individuals were 
included in the current prospective analyses. This study 
was conducted according to the guidelines laid down in 
the Declaration of Helsinki, and all procedures involving 
human participants were approved by the VU University 
Medical Centre Ethics Committee. Written informed con-
sent was obtained from all participants.
Fatty acid profile
A fasting blood sample was drawn for the determination 
of serum total lipids at baseline. The VU Medical Center 
stored the serum samples for ~10 years at −80 °C. Fatty 
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acid profiles in serum total lipids were assayed by gas liq-
uid chromatography with flame ionization detection at AS 
Vitas, Oslo Innovation Center, Oslo, Norway. Serum sam-
ples, thawed in fridge overnight, were vortexed, centri-
fuged, and transferred into new vials. Internal standard (tri-
heptadecanoin) was added, and fatty acids were methylated 
into methyl esters (FAMEs) with MeOH HCl. The FAMEs 
were extracted with hexane. After neutralization with 
KOH in water, mixing and centrifuging, the hexane phase 
was injected into the GC-FID. Analysis was performed on 
an Agilent 7890A GC with a splitless injector, a 7683B 
automatic liquid sampler, and flame ionization detection 
(Agilent Technologies, Palo Alto, CA, USA). Separations 
were obtained using a SP-2380 column (30 m × 0.25 mm 
i.d. × 0.25 µm film thickness) from Supelco (Bellafonte, 
PA, USA). FAMEs were identified by comparison with 
known standards. An external standard containing known 
amounts of relevant FAMEs (Supelco 37 component FAME 
Mix) was included in each run to correct for differences 
in fatty acid response factors. Fatty acid content was cal-
culated based on the area % of peaks and response factors 
relative to 18:0. The method has been validated for quanti-
fication of fatty acids according to US FDA Guidance Doc-
ument on Bioanalytical Method Validation. The inter-assay 
coefficient of variation varied between 2 and 4 %.
Glucose levels
FPG levels were determined in serum by a hexokinase 
method (Roche Diagnostics GmbH, Mannheim, Germany), 
and samples for PLG were taken 2 h after ingestion of a 
standard 75-g oral glucose tolerance test at both examina-
tions. The HbA1c result at baseline was calculated as a 
ratio to hemoglobin by an ion-exchange high-performance 
liquid chromatography (HPLC) based on the separation on 
a Mono-S column (Pharmacia, Uppsala, Sweden). At fol-
low-up HbA1c was measured by a turbidimetric inhibition 
immunoassay. The Diabetes Control and Complications Trial 
(DCCT) standardization of HbA1c was only present in the 
follow-up measurements, so an internal validation between 
HbA1c measurements and DCCT standardization methods 
was needed. Conformity between the two HbA1c measuring 
methods was found that disputes a significant impact of the 
dissimilar laboratory methods on our outcomes [29, 30]. Glu-
cose tolerance status at baseline was determined according to 
the most recent WHO criteria [31, 32]. FPG (≥7.0 mmol/L), 
PLG (≥11.1 mmol/L), and HbA1c (≥6.5 %) were used as 
the cutoff value for classifying T2DM in this study.
Other measurements
BMI and waist–hip ratio (WHR) were assessed at baseline 
and follow-up using a standardized protocol as described 
elsewhere [33]. We collected self-reported information on 
medical history, family history in diabetes, medication use 
and lifestyle factors including physical activity [34]. Par-
ticipants completed a validated semiquantitative FFQ [35] 
about their diet to assess average food intakes. Dietary 
intakes of total energy, total fatty acids, and specific fatty 
acids (En %) were calculated using an extended version 
of the Dutch Food Composition table from 2001 (NEVO) 
[36]. Enzymatic methods (Roche, Mannheim, Germany) 
were used to measure triglycerides and cholesterol values.
Statistical analysis
Baseline characteristics of participants were presented in 
quartiles according to serum proportion of LA and ALA. 
To investigate the linear trend between serum LA or ALA 
and all baseline characteristics, we utilized a crude regres-
sion analysis with continuous measures.
After checking the data for potential effect modification 
by age, sex, use of statins, T2DM, or cohort origin (Hoorn 
study vs. Hoorn screening study), multiple linear regres-
sion tests were performed to investigate the cross-sectional 
association between baseline serum LA or ALA and base-
line glucose parameters (FPG, PLG, and HbA1c). Adjust-
ments were added in a stepwise approach, with Model III 
being the fully adjusted model that included adjustments 
for sex, age, total energy intake (kcal), BMI (kg/m2) and 
WHR (waist/hip ratio), physical activity (PA)(min/week), 
fiber (g/d), total dietary SFA (E %), alcohol (E %) and level 
of education. Additional confounding or mediation was 
addressed by stepwise adding other risk factors for T2DM: 
total cholesterol (mmol/L), use of statins (yes/no), or tri-
glycerides (mmol/L).
Multiple linear regression tests were performed to inves-
tigate the association between serum LA and ALA propor-
tions at baseline and FPG, PLG, and HbA1c at follow-up. 
We adjusted for the baseline levels of FPG, PLG, or HbA1c 
as well as for sex, age, total energy intake, and other risk 
factors similar to the models used in the cross-sectional 
analyses.
In addition to data on serum fatty acids proportions (as 
% of total fatty acids), absolute levels of serum fatty acids 
and data on dietary intake of LA and ALA via a FFQ were 
also available. To examine the validity of serum fatty acid 
proportions as markers of fatty acid intake, the Pearson 
correlation coefficients of total dietary LA and ALA with 
serum proportions and with absolute levels of LA or ALA 
were calculated. The associations between dietary intake of 
LA and ALA and the three blood glucose parameters were 
assessed with linear regression analyses.
SPSS version 18.0 was used for the statistical analyses 
(SPSS Inc. Released 2009. PASW Statistics for Windows, 
version 18.0. Chicago: SPSS Inc). A p value below 0.05 
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was considered statistically significant, except for interac-
tion terms, where we used p < 0.10.
Results
Baseline characteristics
The mean age of the participants was 69 years (SD 7 years), 
and 49 % was male. In total, 128 (28 %) of the 667 study 
participants were newly diagnosed with T2DM. Mean pro-
portions of serum LA and ALA were 26.98 % ± 3.81 and 
0.53 % ± 0.15. The complete fatty acid profile of the popu-
lation is shown in Supplementary Table 1. Characteristics 
of the study subjects across serum LA and ALA quartiles 
are displayed in Table 1. Individuals with higher serum 
LA proportions were more frequently male and had sig-
nificantly lower BMI, WHR, dietary intake of SFA, triglyc-
erides level, statins use and lower proportions of impaired 
fasting glucose (IFG)/impaired glucose tolerance (IGT), 
and T2DM. Also their levels of physical activity, LDL and 
HDL cholesterol levels were significantly higher, as well as 
their dietary intake of LA and ALA (%) and dietary fiber. 
Individuals with higher serum ALA proportions had signifi-
cantly higher levels of physical activity and triglycerides, 
higher dietary ALA and fiber intake, and lower levels of 
HDL cholesterol.
Mean levels of LA were associated with glucose toler-
ance state [27.7 % (3.6) for NGM, 26.5 % (3.8) for IFG/
IGT, and 26.4 % (4.0) for T2DM, ANOVA p value <0.05]. 
Mean levels of ALA were not associated with glucose 
tolerance state [0.54 % (0.15) for NGM, 0.53 % (0.14) 
for IFG/IGT, and 0.52 % (0.17) for T2DM, ANOVA not 
significant].
Cross‑sectional analyses
Baseline serum LA proportions were inversely and sig-
nificantly associated with FPG (B = −0.024 [−0.045, 
−0.002]) and PLG (B = −0.099 [−0.158, −0.039]) in 
the fully adjusted model. For PLG, this result remained 
significant after further adjustment for serum choles-
terol and use of statins (B = −0.096 [−0.156, −0.035]) 
but not triglycerides. Significance was lost for FPG when 
additionally adjusted for cholesterol and statin use and tri-
glycerides. There was no significant association between 
baseline serum LA proportions and baseline HbA1c (see 
Table 2). There was no significant association between 
serum ALA proportions and any of the three baseline blood 
glucose parameters. However, adjustment for triglycer-
ides resulted in an inverse significant association of serum 
ALA with FPG (B = −0.810 [−1.333, −0.288]) and PLG 
(B = −2.335 [−3.837, −0.834]). There were no significant 
interactions between serum levels of LA or ALA and age, 
sex, use of statins, cohort origin, and T2DM (p > 0.10), 
except for the association between serum ALA and FPG, 
which was in the fully adjusted model stronger among sub-
jects not taking statins (p value interaction = 0.052). Asso-
ciations of serum polyunsaturated fatty acid levels other 
than LA and ALA are presented in Supplementary Table 2.
Prospective analyses
After a mean follow-up time of 7.44 ± 0.55 year, 39 
patients (20 male) out of 257 had developed T2DM. As 
shown in Table 3, baseline serum LA proportions were 
inversely and statistically significantly associated PLG 
(B = −0.112 [−0.187, −0.037]) at follow-up in Model I. 
However, this association was no longer statistically signifi-
cant after adjustments for baseline PLG, and other covari-
ates B = −0.026 [−0.100, 0.015], respectively). There was 
no association between baseline serum LA proportions and 
FPG or HbA1c levels at follow-up. Baseline serum ALA 
proportions were not significantly associated with FPG, 
PLG or HbA1c.
Additional analyses
There was a significant correlation between dietary LA 
intake (E %) and serum proportions (% of total fatty acids) 
of LA (r = 0.343, p < 0.001) and a modest correlation 
with concentrations (micrograms/ml) of LA (r = 0.218, 
p < 0.001). There was a weaker correlation between die-
tary ALA intake and serum proportions of ALA (r = 0.134, 
p < 0.001) or concentrations (micrograms/ml) of ALA 
(r = 0.128, p < 0.001). Dietary LA intake was not signifi-
cantly associated with any of the blood glucose parameters 
(B = 0.021 [−0.025, 0.068] for FPG, B = 0.082 [−0.045, 
0.208] for PLG and B = 0.014 [−0.016, 0.043] for HbA1c. 
The same was true for dietary ALA intake (B = 0.249 
[−0.275, 0.773] for FPG, B = 0.937 [−0.520, 2.40] for 
PLG and B = 0.196 [−0.131, 0.524] for HbA1c).
Discussion and conclusion
In the present population-based cross-sectional study, we 
observed significant inverse associations of LA in serum 
with concentrations of FPG and PLG, but not with HbA1c. 
The proportion of ALA in serum was not associated with 
these markers of glucose metabolism. These associations 
were independent of age, sex, total energy intake, obesity, 
and other lifestyle factors. In prospective analyses of this 
same population, however, there were no significant inde-
pendent associations between serum LA and ALA propor-
tions and blood glucose concentrations.
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Strengths and limitations
A major strength of this study is the measurement of the pro-
portions of LA and ALA in serum as markers of their die-
tary intake. Intake of fatty acids can be difficult to estimate 
accurately from FFQ because of misreporting by subjects 
and lack of data on fatty acid content in food composition 
tables [7]. As a result, important associations between fatty 
acid intake and health outcomes can be missed when only 
assessed with dietary fat intake from a FFQ [18]. This is sup-
ported by the current study, in which we found an inverse 
cross-sectional association between serum LA and glucose 
concentration, while this was not observed for dietary LA.
Total fatty acid levels in serum, as measured in the present 
study, originate from different blood lipid fractions including 
triglycerides, cholesteryl esters, phospholipids, and nonester-
ified fatty acids. These lipid fractions reflect dietary intake in 
previous days to weeks at maximum [18]. Short-term dietary 
modifications reflected in serum fatty acids may not trans-
late into changes in risk factors within the same timeframe, 
thereby potentially underestimating the true association. 
Nevertheless, serum LA and ALA levels do reasonably well 
correlate with dietary LA and ALA intake, as assessed via 
FFQ (typically reflecting intake over previous 4 weeks) [18].
An advantage of the current study is that we determined 
FPG, PLG, as well as HbA1c, three markers of different 
aspects of glucose metabolism, that are each considered 
relevant and are accepted for the diagnosis of T2DM [32]. 
This provides the opportunity to investigate the associations 
of serum and dietary LA and ALA with different aspects 
of the glucose metabolism. Other strengths of the current 
study include the population-based prospective design and 
the detailed characteristics of the study population.
Several limitations of our analysis are to be addressed. 
It might be argued that the overrepresentation of T2DM 
patients and persons with impaired glucose tolerance in our 
population limits the generalizability of our findings to other 
populations. On the other hand, the advantage of a population 
with highly prevalent T2DM and impaired glucose tolerance 
is that this enhances the likelihood to detect larger differ-
ences in glucose metabolism between subjects. Regardless, 
the current study and in particular the prospective analyses 
are limited by sample size and may thus lack power to assess 
a potential association with diabetes incidence. Serum fatty 
acid proportions and glucose parameters can be influenced 
by age, sex, total energy intake, obesity, lifestyle factors, and 
other (unknown) confounders. Despite careful adjustments 
for most of these variables, we cannot rule out residual or 
unmeasured confounding. There is also the chance that our 
results were over-adjusted by including waist–hip ratio as 
potential confounder in the model. There are indications that 
PUFA, in comparison with SFA, may reduce abdominal fat 
Table 2  Unstandardized regression coefficients of a cross-sectional linear regression analysis testing the association of serum LA and ALA pro-
portions with three blood glucose parameters
Model I is adjusted for age, sex, and total energy intake
Model II is adjusted for age, sex, total energy intake, BMI, and WHR
Model III is adjusted for age, sex, total energy intake, BMI, WHR, physical activity, fiber, dietary SFA, alcohol, and education level
FPG fasting plasma glucose, PLG post-load glucose, HbA1c glycated hemoglobin, B unstandardized regression coefficient, LA linoleic acid, 
ALA alpha-linolenic acid
Linear regression analyses with * p < 0.05
a Stepwise adjustments (not cumulative) for cholesterol and statins to model III
b Stepwise adjustments (not cumulative) for triglycerides to model III
FPG mmol/L (n = 667) PLG mmol/L (n = 537) HbA1c (%) (n = 664)
B [95 % CI] B [95 % CI] B [95 % CI]
LA (%)
 Model I −0.054 [−0.077, −0.031]* −0.130 [−0.186, −0.074]* −0.006 [−0.019, 0.006]
 Model II −0.027 [−0.050, −0.004]* −0.091 [−0.148, −0.034]* 0.004 [−0.009, 0.017]
 Model III −0.024 [−0.045, −0.002]* −0.099 [−0.158, −0.039]* 0.000 [−0.014, 0.013]
  + Cholesterol and statinsa −0.021 [−0.044, 0.001] −0.096 [−0.156, −0.035]* 0.003 [−0.011, 0.017]
  + Triglyceridesb −0.004 [−0.027, 0.019] −0.054 [−0.117, 0.009] 0.012 [−0.003, 0.026]
ALA (%)
 Model I −0.534 [−1.111, 0.043] −1.192 [−2.680, 0.296] −0.076 [−0.395, 0.244]
 Model II −0.508 [−1.056, 0.041] −1.291 [−2.737, 0.154] −0.088 [−0.404, 0.228]
 Model III −0.292 [−0.794, 0.210] −0.978 [−2.439, 0.482] −0.057 [−0.372, 0.258]
  + Cholesterol and statinsa −0.256 [−0.759, 0.247] −0.894 [−2.366, 0.578] −0.046 [−0.361, 0.268]
  + Triglyceridesb −0.810 [−1.333, −0.288]* −2.335 [−3.837, −0.834]* −0.319 [−0.650, 0.012]
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[37], which could lead to a reduction in blood glucose. The 
waist–hip ratio reflecting abdominal fat could thus be in the 
causal pathway from dietary and serum LA to T2DM, in 
which case the adjustment for waist–hip ratio would under-
estimate their relationship in the population. Another study 
limitation is that the proportions of LA and ALA in serum 
were assessed only once at baseline. Potential changes in 
intake of LA and ALA over time could have caused mis-
classification of long-term dietary exposure and in this way 
underestimation of the underlying association.
Current findings in the context of other studies
As in most epidemiological studies, serum fatty acid levels 
in the current study were measured and expressed as propor-
tion of total fatty acids. We observed that the correlation of 
dietary LA and ALA intake with serum proportions of LA 
and ALA is stronger than the correlation with concentrations 
of LA and ALA (present study). This may favor the expres-
sion of LA and ALA as a proportion of total fatty acids.
We found that higher proportions of serum LA in 
cross-sectional analyses were associated with lower lev-
els of blood glucose concentrations. These findings are in 
line with results from earlier prospective cohort studies on 
the relationship between serum LA and T2DM incidence 
[13, 14, 19–23]. Our findings are also largely in line with 
results from a recent systematic review, which concluded 
that higher serum levels of ALA tend to be associated with 
lower risk of T2DM [24]. LA or ALA proportions in serum 
did not show an association with HbA1c. This may suggest 
that for HbA1c physiological and pathological determinants 
other than diet are more important than for glucose [29].
There was a weak correlation between serum ALA and 
markers of blood glucose metabolism in our study, which 
has also been observed in other studies [38]. It has been 
suggested to be the result of rapid oxidation of dietary ALA 
in the body [39] or of measurement error in the intake data 
including underlying food composition tables [38].
Potential mechanisms
Biological mechanisms underlying a possible relation 
between dietary and serum fatty acids and risk of T2DM 
are not completely understood. It has been hypothesized 
that consuming a diet with a high ratio of PUFA to SFA 
increases the PUFA content of phospholipids, which may 
improve the glucose transport, oxidation, and lipogenesis 
[40]. The ratio of PUFA to SFA may influence the flex-
ibility of the cell membrane, cellular function, and insu-
lin signaling leading to an increase in insulin sensitivity 
Table 3  Unstandardized regression coefficients of a prospective linear regression analysis testing the association of LA and ALA serum propor-
tions at baseline with three blood glucose parameters at follow-up
Model I is adjusted for age, sex, and total energy intake
Model II is adjusted for age, sex, total energy intake, and baseline glycemic measure
Model III is adjusted for age, sex, total energy intake, baseline glycemic measure, BMI, WHR, physical activity, fiber, dietary SFA, alcohol, and 
education level
FPG fasting plasma glucose, PLG post-load glucose, HbA1c glycated hemoglobin, B unstandardized regression coefficient, LA linoleic acid, 
ALA alpha-linolenic acid
Linear regression analyses with * p < 0.05
a Stepwise adjustments (not cumulative) for cholesterol and statins to model III
b Stepwise adjustments (not cumulative) for triglycerides to model III
FPG mmol/L (n = 257) PLG mmol/L (n = 253) HbA1c (%) (n = 257)
B [95 % CI] B [95 % CI] B [95 % CI]
LA (%)
 Model I −0.025 [−0.050, 0.000] −0.112 [−0.187, −0.037]* −0.012 [−0.025, 0.001]
 Model II −0.005 [−0.025, 0.016] −0.054 [−0.123, 0.015] −0.010 [−0.021, 0.001]
 Model III 0.003 [−0.019, 0.025] −0.026 [−0.100, 0.049] −0.007 [−0.019, 0.005]
  + Cholesterol and statinsa 0.004 [−0.019, 0.026] −0.045 [−0.124, 0.033] −0.002 [−0.015, 0.010]
  + Triglycerideb 0.004 [−0.019, 0.026] −0.045 [−0.124, 0.033] −0.002 [−0.015, 0.010]
ALA (%)
 Model I −0.009 [−0.601, 0.584] −1.616 [−3.426, 0.195] 0.043 [−0.260, 0.346]
 Model II 0.107 [−0.371, 0.585] −1.240 [−2.853, 0.372] 0.065 [−0.198, 0.327]
 Model III 0.107 [−0.374, 0.588] −1.098 [−2.716, 0.521] 0.072 [−0.191, 0.336]
  + Cholesterol and statinsa 0.114 [−0.375, 0.603] −1.044 [−2.765, 0.677] 0.128 [−0.152, 0.408]
  + Triglyceridesb 0.114 [−0.375, 0.603] −1.044 [−2.765, 0.677] 0.128 [−0.152, 0.408]
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when more PUFA is consumed. Indeed, one interven-
tion trial in which PUFA was replaced by SFA reported 
a beneficial effect on insulin sensitivity [41]. In the pre-
sent study, serum LA proportions showed a significant 
inverse association with both FPG and PLG. This is plau-
sible given that FPG and PLG are the primary markers 
of insulin sensitivity in the liver and the peripheral tis-
sues, respectively [42]. Part of the observed association 
between LA proportions and T2DM risk in our study was 
explained by differences in triglyceride levels. Dyslipi-
demia, involving elevated triglyceride levels, is a common 
characteristic in patients with T2DM [43]. In addition, 
since the proportion of LA varies between lipid spe-
cies, the lipid levels may have confounded the relation-
ship between LA and glucose. In cholesteryl esters, LA 
compose over half of fatty acids, whereas in triglycerides 
the proportion of LA is about 15 % and in phospholip-
ids about 20 %. This implies that among individuals with 
higher concentrations of triglycerides, the proportion of 
LA in total serum is lower [18]. However, the causality of 
the relationship between LA proportion and lipid species 
is poorly understood. One might suggest that increases in 
triglycerides lead to a reduction in LA levels. On the other 
hand, changes in triglycerides, and its associated etiolo-
gies insulin resistance and ectopic fat deposition may be 
the result of dietary LA intake. The latter is supported by 
controlled human dietary intervention studies, in which 
PUFA as replacement of SFA reduced liver fat [44, 37] 
and insulin resistance [41]. In addition, a meta-analysis 
of 60 controlled intervention studies on blood lipids has 
established that dietary PUFA intake reduce triglyceride 
levels compared with carbohydrates [1]. Thus, adjustment 
for triglycerides in our models will correct for variation 
in LA between lipid species, but may lead to underesti-
mation of the true association because it partially corrects 
for triglycerides as an intermediate in the causal pathway 
toward higher glucose levels. Therefore, we assume that 
true association between LA and glucose levels may lie 
in between the associations estimated by the triglyceride-
adjusted and unadjusted models.
The proportion of LA in serum fatty acid is not solely 
influenced by LA intake, but also by endogenous fatty acid 
metabolism [38]. For example, an increased Δ6-desaturase 
activity, resulting in lower serum LA, has been associated 
with insulin resistance and T2DM [45, 46]. Therefore, 
reversed causality cannot be excluded as an explanation 
for the observed association. For the present study, how-
ever, this is not very likely given that Δ6-desaturase activ-
ity (estimated as C18:3n6/C18:2n6 ratio) in T2DM subjects 
was not significantly different from nondiabetic subjects 
(data not shown). The biological mechanisms by which 
different types of PUFAs might affect glucose metabolism 
remain to be elucidated.
Conclusion
In this population with overrepresentation of subjects with 
glucose intolerance, serum LA was inversely associated 
with fasting and post-load glucose in cross-sectional, but 
not in prospective analyses. Further studies are needed to 
elucidate the potential role of serum LA and ALA levels 
and dietary PUFA in glucose metabolism.
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